[Dexmedetomidine improves function of lung oxygenation in patients with moderate chronic obstructive pulmonary disease underwent lung cancer surgery].
To determine whether dexmedetomidine (Dex) improves oxygenation and lung mechanics in patients with moderate chronic obstructive pulmonary disease (COPD) during lung cancer surgery. Methods: Fifty-six patients with moderate COPD were randomly allocated to a control group and a Dex group (n=28 each). In the Dex group, dexmedetomidine was given as an initial loading dose at 1.0 μg/kg lasting for 10 min followed by a maintenance dose at 0.5 μg/(kg.h) during OLV while the control group was administered an equal volume of 0.9% saline accordingly. Results: Patients in the Dex group had a significantly higher oxygenation index (P<0.05) and higher dynamic lung compliance at Dex-30 and Dex-60 (P<0.05) compared with those in the control group. In the Dex group, oxygenation index in the postoperative period was significantly higher (P= 0.025) and postoperative complications were lower than those in the control group. Conclusion: Dex administration may provide clinically relevant benefits by improving o xygenation index and lung mechanics, and reducing postoperative pulmonary complications in patients with moderate COPD underwent lung cancer surgery.